...
首页> 外文期刊>Current Drug Therapy >Novel Therapeutic Agents for Resistant Gram-Positive Infections
【24h】

Novel Therapeutic Agents for Resistant Gram-Positive Infections

机译:抗革兰氏阳性感染的新型治疗剂

获取原文
获取原文并翻译 | 示例
           

摘要

Multiresistant Gram-positive cocci, including Staphylococcus aureus, the group of coagulase-negative staphylococci, Enterococcus faecalis and Enterococcus faecium, as well as Streptococcus pneumoniae and other streptococci, represent emerging pathogens in the community, but especially in the setting of immunocompromised, hospitalized patients. In these last subjects, it happens in particular when surgery, invasive procedures, or prosthetic implants are of concern, patients are admitted in intensive care units, or underlying chronic disorders and immunodeficiency are of concern, and broad-spectrum antibiotics are widely used in the environment. The spectrum of antimicrobial compounds now available for an effective management and treatment of these relevant infections is significantly threatened by the emerging and spread of methicillin-resistant and more recently glycopeptide-resistant microbial strains. The streptogramine association represented by quinupristin/dalfopristin, the oxazolidinone derivative linezolid, and the recently licensed daptomycin and tigecycline, together with a number of glycopeptides, quinolones, and other experimental compounds on the pipeline, represent an effective response to the majority of these problems, due to their innovative mechanisms of action, their maintained or enhanced activity against multiresistant pathogens, their effective pharmacokinetic/pharmacodynamic properties, their frequent possibility of synergistic activity with other compounds effective against Gram-positive pathogens, and a diffuse potential for a safe and easy administration, also to compromised patients. The main problems related to the epidemiology of multiresistant gram-positive infection, the potential clinical indications of all recently available compounds compared with the standard of care of treatment of resistant Gram-positive infections, and updated data on efficacy and tolerability of all these compounds, are updated and outlined based on an extensive review of all available, recent evidences from the international literature.
机译:多重耐药的革兰氏阳性球菌,包括金黄色葡萄球菌,凝固酶阴性葡萄球菌,粪肠球菌和粪肠球菌,以及肺炎链球菌和其他链球菌,代表了社区中正在出现的病原体,但在免疫功能低下,住院患者中尤为如此。在这些最后的受试者中,尤其是在需要考虑外科手术,侵入性手术或假体植入,将患者送入重症监护病房,或者需要关注潜在的慢性疾病和免疫缺陷以及广谱抗生素被广泛使用时,会发生这种情况。环境。现在可用于有效管理和治疗这些相关感染的抗菌化合物的种类受到耐甲氧西林和最近抗糖肽耐药的微生物菌株的出现和传播的严重威胁。以奎奴普丁/达福普汀,恶唑烷酮衍生物利奈唑胺和最近获得许可的达托霉素和替加环素为代表的链霉菌素结合物,以及正在研发的许多糖肽,喹诺酮和其他实验化合物,代表了对大多数这些问题的有效反应,由于其创新的作用机制,对多重耐药病原体的维持或增强的活性,有效的药代动力学/药效学特性,与其他有效对抗革兰氏阳性病原体的化合物经常具有协同活性的可能性以及安全和简便给药的分散潜力,也要折衷患者。主要问题涉及多药耐药的革兰氏阳性感染的流行病学,与抗药性革兰氏阳性感染的治疗标准相比,最近所有可用化合物的潜在临床适应症,以及所有这些化合物的疗效和耐受性的最新数据,在对国际文献中所有可用的最新证据进行广泛审查的基础上,对本指南进行了更新和概述。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号